Canada-based commercialisation firm Mars Innovation secured an $800,000 commitment on Monday from pharmaceutical firm Pfizer to establish a translational research fund.
The Mars Innovation – Pfizer Translational Research Fund will focus on technologies in life sciences, including therapeutics, diagnostic and treatment tools, manufacturing and research-enabling products.
The fund will particularly seek to identify projects related to rare diseases, cancer, vaccines, inflammation, immunology and cardiovascular disease. It will be managed by Mars Innovation.
Raphael Hofstein, president and CEO of Mars Innovation,…